Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
Historisch | Analysen | |||||
Ausblick |
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
Inhaber | in % |
---|---|
Hoffmann Family | 64.97 |
Freefloat | 27.20 |
Maja Oeri | 7.58 |
Stichting Pensioenfonds ABP (Global Equity Portfolio) | 1.39 |
RBC Global Equity Focus Fund | 0.92 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2018 | 2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 94'442 | 97'735 | 101'465 | 100'920 | 103'613 |
Umsatz pro Mitarbeiter in Mio. EUR | 0.60 | 0.63 | 0.57 | 0.62 | 0.61 |
Bilanz (in Mio. EUR) - Aktiva
2018 | 2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 32'244 | 31'254 | 32'942 | 35'627 | 33'816 |
Summe Anlagevermögen | 46'392 | 48'329 | 51'752 | 57'041 | 54'536 |
Summe Aktiva | 78'517 | 83'091 | 86'138 | 92'317 | 88'151 |
Bilanz (in Mio. EUR) - Passiva
2018 | 2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|---|
Gesamtverschuldung/ -verbindlichkeiten | 18'770 | 15'582 | 15'411 | 32'552 | 26'544 |
Summe Fremdkapital | 48'151 | 47'224 | 46'365 | 63'972 | 56'136 |
Summe Eigenkapital | 30'366 | 35'867 | 39'773 | 28'345 | 32'015 |
Summe Passiva | 78'517 | 83'091 | 86'138 | 92'317 | 88'151 |
Adresse
Grenzacherstrasse 124, 4058 Basel | |
Telefon | +41 (61) 688-11-11 |
Fax | +41 (61) 691-93-91 |
URL | http://www.roche.com |
Management
Akiko Iwasaki
Director |
Alan Hippe
Chief Financial & Information Officer |
André S. Hoffmann
Vice Chairman |
Anita Hauser
Independent Non-Executive Director |
Annette Luther
Secretary |
Bernard J. Poussot
Independent Non-Executive Director |
Bruno Eschli
Head-Investor Relations |
Claudia Boeckstiegel
General Counsel |
Claudia Süssmuth Dyckerhoff
Independent Non-Executive Director |
Cristina A. Wilbur
Chief People Officer |
Hans Clevers
Head-Pharma Research & Early Development |
Jemilah Mahmood
Director |
Joerg Duschmale
Independent Non-Executive Director |
Levi A. Garraway
Chief Medical Officer & Head-Product Development |
Pascale Schmidt
Chief Compliance Officer |
Patrick Frost
Independent Non-Executive Director |
Richard P. Lifton
Independent Non-Executive Director |
Severin Schwan
Chairman |
Silke Hörnstein
Head-Corporate Strategy & Sustainability |
Thomas Schinecker
Chief Executive Officer |
Ulf Mark Schneider
Director |